Yifan Pharmaceutical (SHE: 002019) announced that it has officially signed a commercialization agreement with Eisai Co., Ltd. (TYO: 4523). Under the terms, Yifan Pharmaceutical will obtain exclusive rights to import, sell, distribute, and promote Halaven (generic name: eribulin mesylate injection), an originator anti‑tumor drug owned by Eisai, in Mainland China. Halaven – a halichondrin‑class microtubule dynamics inhibitor – is approved for breast cancer in over 70 countries and has been marketed in China since July 2019 for previously treated locally advanced or metastatic breast cancer.
Deal Snapshot
| Item | Detail |
|---|---|
| Parties | Yifan Pharmaceutical (SHE: 002019) and Eisai Co., Ltd. (TYO: 4523) |
| Agreement Type | Commercialization agreement |
| Product | Halaven (eribulin mesylate injection) – originator anti‑tumor drug |
| Rights Granted | Exclusive rights to import, sell, distribute, and promote |
| Territory | Mainland China |
| Announcement Date | 21 Oct 2026 |
| Financial Terms / Transaction Value | Not disclosed |
| Transition Timeline | Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: Eribulin mesylate, a halichondrin‑class microtubule dynamics inhibitor.
- Differentiated Mechanism: A mechanism of action distinct from traditional taxane‑based microtubule inhibitors, offering a non‑cross‑resistant option within the microtubule‑targeting class of chemotherapy.
- Originator Brand: Halaven, developed and owned by Eisai, one of the longest‑established originator brands in metastatic breast cancer therapy.
- Administration: Injectable formulation (eribulin mesylate injection).
Regulatory & Commercial History
| Item | Detail |
|---|---|
| First Approval | United States, November 2010 – metastatic breast cancer |
| Global Footprint | Approved for breast cancer in over 70 countries worldwide |
| China Approval | July 2019 |
| China Indication | Locally advanced or metastatic breast cancer in patients who have previously received at least two chemotherapy regimens, including an anthracycline and a taxane |
Market Impact & Outlook
- Exclusive China Commercialization: The agreement consolidates Halaven’s Mainland China presence under Yifan Pharmaceutical’s commercial infrastructure, with exclusive import, sales, distribution, and promotion rights – aligning a proven originator asset with local market execution.
- Portfolio Fit: Adding an originator anti‑tumor brand strengthens Yifan’s oncology portfolio beyond generics, targeting the heavily pretreated metastatic breast cancer segment where treatment options after anthracyclines and taxanes remain limited.
- Differentiated Class Positioning: Halaven’s non‑taxane microtubule mechanism provides oncologists an alternative for patients who have progressed through standard taxane therapy – a clinically meaningful niche in late‑line breast cancer care.
- Breast Cancer Burden: China carries one of the world’s largest breast cancer populations, with substantial demand for late‑line therapies; market access strategy, pricing, and reimbursement plans for the transition were not disclosed.
- Next Steps: Execution of the commercialization transition in Mainland China; financial terms and operational timelines remain not disclosed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the Yifan Pharmaceutical–Eisai commercialization agreement for Halaven in Mainland China, including anticipated commercialization activities and market potential. Actual results may differ materially due to risks including execution of the commercial transition, pricing and reimbursement environment in China, competitive therapies, supply and regulatory considerations, and changes to the agreement terms.-Fineline Info & Tech
